PHIO

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: BLRX CYCN ERNA GDTC GNTA GTBP ICU INTS RKTO TOVX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	11.85M
Enterprise Value	-5.18M
Income	-10.93M
Sales	0.00M
Book/sh	1.42
Cash/sh	1.47
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	May 10, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.72
P/C	0.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.32
Current Ratio	18.32
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.44
EPS next Y	-0.86
EPS next Q	-0.36
EPS this Y	5.17%
EPS next Y	37.45%
EPS next 5Y	-
EPS past 3/5Y	74.81% 62.91%
Sales past 3/5Y	- -
EPS Y/Y TTM	77.90%
Sales Y/Y TTM	-
EPS Q/Q	16.09%
Sales Q/Q	-
Earnings	May 07
EPS/Sales Surpr.	-44.68% -

Insider Own	10.71%
Insider Trans	0.81%
Inst Own	5.75%
Inst Trans	2.48%
ROA	-70.87%
ROE	-76.36%
ROIC	-66.41%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.02%
SMA50	-5.42%
SMA200	-22.56%
Trades

Shs Outstand	11.62M
Shs Float	10.37M
Short Float	2.11%
Short Ratio	1.33
Short Interest	0.22M
52W High	4.19 -75.66%
52W Low	0.81 25.51%
Volatility	6.35% 4.87%
ATR (14)	0.05
RSI (14)	46.44
Beta	0.82
Rel Volume	0.40
Avg Volume	163.86K
Volume	65,035

Perf Week	2.00%
Perf Month	-5.56%
Perf Quarter	-18.40%
Perf Half Y	-15.70%
Perf YTD	-2.86%
Perf Year	-58.28%
Perf 3Y	-96.12%
Perf 5Y	-99.55%
Perf 10Y	-100.00%
Recom	1.00
Target Price	14.00
Prev Close	1.04
Price	1.02
Change	-1.92%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Resumed	H.C. Wainwright	Buy	$14
Aug-05-20	Initiated	H.C. Wainwright	Buy	$4

Jun-26-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Jun-25-26 07:00AM	Phio Pharmaceuticals Announces 'How siRNA Therapy can Change the Course of Cancer Treatment' in a Fireside Chat with Force Family Office on Monday, June 29, 2026 (Newsfile) -5.90%
Jun-24-26 07:00AM	Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 (Newsfile Corp.)
Jun-18-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 (Newsfile)
May-26-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
07:00AM	Loading…
May-12-26 07:00AM	Phio Pharmaceuticals Announces 'Innovations in Skin Cancer Treatment and Prevention' in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026 (Newsfile)
May-07-26 04:05PM	Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update (Newsfile) -6.14%
Apr-23-26 07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Apr-13-26 07:00AM	Phio Pharmaceuticals Announces 'Nobel Prize Winning Science Takes on Skin Cancer' in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 (Newsfile)
Apr-09-26 07:00AM	Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 (Newsfile)
Mar-30-26 07:00AM	Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 (Newsfile Corp.)
Mar-23-26 07:00AM	Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement (Newsfile)
Mar-16-26 11:30AM	Phio Pharmaceuticals Announces 'A Groundbreaking Approach to Treating Skin Cancer' in a Fireside Chat with Force Family Office (Newsfile) +7.69%
Mar-10-26 07:00AM	Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT (Newsfile)
Mar-05-26 04:05PM	Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update (Newsfile)
07:00AM	Loading…
07:00AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Feb-23-26 09:45AM	Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company (NewMediaWire)
Feb-19-26 07:00AM	Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 (Newsfile)
Feb-12-26 08:43AM	What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? (Benzinga) -5.43%
Feb-10-26 11:12AM	Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients (Benzinga) +24.44%
07:00AM	Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial (Newsfile)
Jan-26-26 08:15AM	Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference (Newsfile)
Jan-20-26 09:30AM	Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial (Newsfile) -5.26%
Jan-15-26 08:45AM	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 (Newsfile)
Dec-23-25 08:45AM	Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 (Newsfile) -6.36%
Nov-25-25 11:30AM	Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 (Newsfile)
Nov-17-25 08:45AM	Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress (Newsfile)
Nov-13-25 04:15PM	Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Newsfile) -9.49% -9.09%
Nov-07-25 10:30AM	Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 (Newsfile) +5.41%
07:45AM	Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program (Newsfile)
01:40PM	Loading…
Nov-03-25 01:40PM	Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds (Newsfile) -9.27%
07:45AM	Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial (Newsfile)
Oct-31-25 10:15AM	Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director (Newsfile)
Oct-21-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Sep-23-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series (Newsfile)
Sep-18-25 07:45AM	Phio Pharmaceuticals to Present at the Life Sciences Future Conference (Newsfile)
Sep-03-25 07:45AM	Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Aug-14-25 04:15PM	Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Newsfile)
Jul-25-25 03:04PM	Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds (Newsfile) +9.16%
12:36PM	Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort (Newsfile)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:45AM	Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance (Newsfile)
Jun-25-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort (Newsfile)
Jun-24-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jun-06-25 07:45AM	Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio (Newsfile) +20.33%
May-28-25 09:02AM	Best Value Stocks to Buy for May 28th (Zacks) +16.96%
04:37AM	New Strong Buy Stocks for May 28th (Zacks)
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-19-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference (Newsfile)
May-15-25 04:15PM	Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Newsfile)
May-07-25 07:45AM	Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial (Newsfile) +18.60%
May-01-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Apr-23-25 10:15AM	Best Momentum Stocks to Buy for April 23rd (Zacks) -18.73%
06:45AM	Best Value Stocks to Buy for April 23rd (Zacks)
Apr-10-25 10:53AM	PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose (Zacks) +7.14%
Apr-09-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort (Newsfile) +52.48%
Apr-03-25 07:45AM	Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 (Newsfile)
Mar-31-25 04:00PM	Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update (Newsfile) -5.38%
Mar-10-25 07:45AM	American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting (Newsfile)
Mar-05-25 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study (Newsfile) +5.30%
Feb-26-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Feb-20-25 07:45AM	Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors (Newsfile)
Feb-03-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jan-22-25 07:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.66%
Jan-21-25 11:15AM	Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -10.47%
Jan-16-25 01:00PM	Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +9.40%
Jan-15-25 07:00AM	Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -25.70%
Jan-14-25 07:00AM	Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -45.76%
Jan-13-25 12:45PM	Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why (Benzinga) +290.53%
07:45AM	Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 (Newsfile)
Jan-02-25 07:45AM	Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology (Newsfile) +5.56%
Dec-23-24 01:15PM	Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +26.70%
Dec-19-24 02:28PM	Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -30.68%
07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 (Newsfile)
Dec-12-24 09:21AM	Phio Pharmaceuticals Announces Publication in Frontiers in Immunology (Newsfile) +6.34%
Dec-10-24 07:45AM	Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award (Newsfile)
Dec-03-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Nov-19-24 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study (Newsfile) +12.42%
Nov-14-24 05:47PM	Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Newsfile) -5.11%
Nov-07-24 10:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Nov-01-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Oct-24-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Oct-18-24 01:30PM	Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +9.81%
08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series (Newsfile)
Oct-16-24 08:00AM	Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference (Newsfile) +17.75%
Oct-07-24 08:00AM	Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells (Newsfile) -6.17%
Oct-02-24 04:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -6.47%
Oct-01-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference (Newsfile)
Sep-25-24 08:00AM	INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society (Newsfile)
Sep-17-24 08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +11.64%
Sep-16-24 08:00AM	Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA (Newsfile)
Sep-09-24 07:00AM	Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Newsfile) +6.13%
Aug-29-24 08:30AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.37%
Aug-14-24 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Aug-06-24 08:00AM	Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound (Newsfile)
Aug-01-24 08:00AM	Phio Pharmaceuticals Announces New Chief Financial Officer (Newsfile) -7.34%
Jul-12-24 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds (Newsfile) -13.60%
Jul-08-24 08:00AM	Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 (Newsfile) +9.06%
Jul-05-24 08:00AM	Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds (Newsfile)
Jul-02-24 11:45AM	Phio Pharmaceuticals Announces Reverse Stock Split (Newsfile) -9.17%

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

PresidentMr. Robert J. Bitterman

CFOMs. Lisa C. Carson

Senior Vice President of DevelopmentMs. Linda M. Mahoney

Senior Vice President of Regulatory & Corporate AffairsDr. Jennifer Phillips Pharm.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bitterman Robert J	Chairman, Pres. & CEO	Jun 26 '26	Buy	0.99	10,000	9,900	421,421	Jun 29 04:02 PM
Bitterman Robert J	Chairman, Pres. & CEO	Dec 31 '25	Buy	1.03	5,000	5,150	291,421	Jan 02 04:05 PM
Bitterman Robert J	Chairman, Pres. & CEO	Dec 23 '25	Buy	1.02	5,000	5,100	286,421	Dec 29 08:10 AM
Bitterman Robert J	Chairman, Pres. & CEO	Nov 21 '25	Buy	1.14	5,000	5,700	281,421	Nov 24 12:54 PM
Bitterman Robert J	Chairman, Pres. & CEO	Nov 18 '25	Buy	1.27	5,000	6,350	276,421	Nov 19 12:47 PM

Phio Pharmaceuticals Corp

Upgrade your Finviz experience